Publication | Open Access
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
1.3K
Citations
6
References
2018
Year
Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).
| Year | Citations | |
|---|---|---|
Page 1
Page 1